Detalhe da pesquisa
1.
Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States.
BMC Public Health
; 24(1): 611, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38408941
2.
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
Br J Clin Pharmacol
; 84(5): 961-971, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29345798
3.
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
J Hepatol
; 64(2): 292-300, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26453968
4.
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
; 384(9941): 414-26, 2014 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24907224
5.
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet
; 384(9941): 403-13, 2014 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24907225
6.
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Gastroenterology
; 146(7): 1669-79.e3, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24602923
7.
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
Gastroenterology
; 146(2): 430-41.e6, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24184810
8.
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.
Hepatology
; 58(6): 1918-29, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23907700
9.
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.
Nat Rev Gastroenterol Hepatol
; 19(11): 727-745, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35859026
10.
Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study.
AIDS Res Hum Retroviruses
; 23(9): 1105-13, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17919105
11.
Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
Clin Pharmacokinet
; 55(2): 197-208, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26353895
12.
Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
AIDS
; 19(3): 279-86, 2005 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-15718838
13.
Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment.
Drugs R D
; 15(3): 261-70, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26248593
14.
Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.
J Med Chem
; 57(5): 1673-93, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24446688